** Shares in Swiss medical device firm Medacta MOVE.S are
seen dropping 5.8% at open
** The company cut its FY guidance on Thursday after weaker
than expected sales in the U.S. urn:newsml:reuters.com:*:nASN0000X7
** "The magnitude of the shortfall (...) is worrying,"
Credit Suisse says, adding that it points to rapidly slowing
growth trends
** JP Morgan points to the fact that at the time of the
company's listing (April 2019), the U.S. business was to be a
growth driver going forward
** It sees the profit warning putting Medacta's stock "under
major near-term pressure"
** JP Morgan adds that the market will need to wait a long
time before the issues are fully understood, as Medacta will
post FY results only in April 2020
((Linda.pasquini@tr.com))